Frezent has advantage over immunotherapies such as Pembrolizumab/Keytruda which has limited effect on dormant cells or immune evasive cells and only focuses on actively dividing cancer cells.

Current therapies like Imatinib are effective in mutation-driven, proliferating tumors but leave dormant cancer cells untouched, as these cells rely on metabolic adaptation. Similarly, kinase inhibitors such as Everolimus modulate metabolism indirectly through mTOR/VEGF pathways without targeting the core energy drivers of dormancy.
Frezent directly disrupts the energy/metabolic lifeline of dormant cells - addressing the root of survival rather.

Compared to targeted therapy Venetoclax - which induces apoptosis with limited clinical utility in solid tumors due to high toxicity and tumor lysis risk, Frezent cause highly selective metabolic disruption without systemic toxicity.